Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $18.54 which represents a decrease of $-2.99 or -13.89% from the prior close of $21.53. The stock opened at $19.18 and ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) shares soared to an all-time high this week, reaching a peak of $24.44. According ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...

UBS lowered the firm’s price target on Teva (TEVA) to $27 from $30 and keeps a Buy rating on the shares. UBS says the pullback on the stock ...

Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...